Company Encyclopedia
View More
name
Synopsys
SNPS.US
Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. It operates in two segments, Design Automation and Design IP. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; FPGA design products that are programmed to perform specific functions; synopsys technology computer-aided design (TCAD), mask synthesis, and manufacturing analytic solutions; and AI-driven EDA solutions.
2.733 T
SNPS.USMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
C
Application SoftwareIndustry
Industry Ranking77/256
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.16%B
    • Profit Margin18.89%A
    • Gross Margin81.41%A
  • Growth ScoreB
    • Revenue YoY15.12%B
    • Net Profit YoY-41.14%D
    • Total Assets YoY268.87%A
    • Net Assets YoY213.94%A
  • Cash ScoreB
    • Cash Flow Margin529.51%C
    • OCF YoY15.12%B
  • Operating ScoreD
    • Turnover0.23D
  • Debt ScoreC
    • Gearing Ratio41.26%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pomerantz LLP Notifies Shareholders of Class Action Filing Against Synopsys, Inc. – SNPS

    Pomerantz LLP has filed a class action lawsuit against Synopsys, Inc. for alleged securities fraud. The lawsuit follows Synopsys's third quarter 2025 financial results, which showed a significant decline in revenue and net income, leading to a 35.84% drop in stock price. Shareholders have until December 30, 2025, to join the lawsuit as Lead Plaintiff. Pomerantz LLP is known for its expertise in securities class actions.

    Acceswire·
    US
    SNPS
    -5.09%
    Acceswire·
    US
    SNPS
    -5.09%

    Mizuho Securities Sticks to Their Buy Rating for Synopsys (SNPS)

    Mizuho Securities analyst Siti Panigrahi reiterated a Buy rating for Synopsys on December 11, with shares closing at $477.26. Panigrahi, with a 0.0% average return and 48.76% success rate, covers the Technology sector. Synopsys also received a Buy rating from TR | OpenAI – 4o’s Elisa Scalantra, while Wells Fargo maintained a Hold rating.

    Tip Ranks·
    US
    SNPS
    -5.09%
    Tip Ranks·
    US
    SNPS
    -5.09%

    Pomerantz LLP Notifies Shareholders of Class Action Against Synopsys, Inc. – SNPS

    Pomerantz LLP has filed a class action lawsuit against Synopsys, Inc. for alleged securities fraud. Shareholders can contact Danielle Peyton to join the lawsuit. Synopsys reported disappointing Q3 2025 financial results, with revenue and net income declining significantly. The company's stock price fell sharply following the news. The deadline to become Lead Plaintiff is December 30, 2025.

    Acceswire·
    US
    SNPS
    -5.09%
    Acceswire·
    US
    SNPS
    -5.09%

    Stock market ends lower; Moderna plunges on FDA memo, Synopsys & Nvidia rise. Dow falls, vaccine-linked deaths discussed.

    Today, the Dow experienced a decline on the stock market. Moderna faced a setback following an FDA memo that associated Covid vaccines with deaths. Likewise, a gold stock made significant gains. The day ended with indexes concluding lower, with Moderna plummeting due to the FDA memo, while Synopsys and Nvidia saw impressive increases.

    Unusual Whales·
    US
    SNPS
    -5.09%
    US
    NVDA
    -3.27%
    US
    MRNA
    -0.57%
    Unusual Whales·
    US
    SNPS
    -5.09%
    US
    NVDA
    -3.27%
    US
    MRNA
    -0.57%

    Key facts: Synopsys Q3 Revenue Misses Expectations; Plans Joint Solutions

    On September 9, 2025, Synopsys reported Q3 revenue of $1.740 billion, below expectations, with net income down 43% year-over-year. Stock fell 35.84% to $387.78 on September 10.1Synopsys plans to launch joint solutions with Ansys in the first half of 2026, while a partnership with NVIDIA is expected to boost product demand across industries such as AI and automotive.2

    TradingView·
    US
    SNPS
    -5.09%
    TradingView·
    US
    SNPS
    -5.09%
    Posts
    View More

    Synopsys QOct25

    - Revenue up 30% q/q and 38% y/y to $2.25B, driven Ansys contribution; Ex-Ansys revenue down by 4% q/q; QJan revenue will grow 6% q/q

    - Both EDA and P down q/q and IP down sharply y/y; F......
    • 0

    Cadence seem happy with its NVIDIA relationship despite the latter's $2B investment in Synopsys. Says NVDA business growing. CDNS's hardware platforms widely used by NVDA. Also, CDNS is making progres...

    • 0

    Cadence made a late entry into the IP market vs Synopsys but made a good progress in recent years. Between Tensilica IP and design IP (SerDes/C2C/HB/DDR), CDNS is seeing its IP growth rate beat EDA gr...

    • 0

    $NVIDIA(NVDA.US)

    Everyone is talking about competition today but I am looking at the expanded partnership with Synopsys. This is the real signal that matters to me.

    ​Nvidia is embedding itself deeper in...

    • 0
    © 2025 Longbridge｜Disclaimer